Why the study?
Calcium channel blockers are used to treat CVD and hypertension, but their effect on survival remains uncertain, and they impair fibrinolysis and have been linked to elevated homocysteine.
Does calcium channel blocker treatment increase mortality in patients with suspected stable angina pectoris, and is this risk modified by B-vitamin treatment?
Does calcium channel blocker treatment increase mortality in patients with suspected stable angina pectoris, and is this risk modified by B-vitamin treatment?
In patients with suspected stable angina pectoris, calcium channel blocker treatment was associated with an increased risk of mortality, which appeared to be mitigated by concurrent B-vitamin treatment.
Answers are grounded in this paper and cite their sources.
CCB use was associated with higher homocysteine; leaves open effects on survival or B-vitamin benefit in CVD patients.
BACKGROUND: Calcium channel blockers (CCBs) are used for the treatment of cardiovascular disease (CVD), including angina pectoris, and hypertension; however, the effect on survival remains uncertain. CCBs impair fibrinolysis and have been linked to elevated plasma homocysteine (Hcy), a CVD risk marker. OBJECTIVE: ) as 61.8% of the patients participated in a randomized placebo-controlled B-vitamin intervention trial. METHODS: Patient baseline continuous characteristics according to CCB treatment were tested by linear regression. Hazard ratios (HRs) for mortality associated with CCB treatment, also according to B-vitamin intervention, were examined using Cox regression analysis. The multivariable model included CVD risk factors, medical histories, and the use of CVD medications. RESULTS: A total of 3991 patients (71.5 % men) were included, of whom 907 were prescribed CCBs at discharge. During 10.3 years of median follow-up, 20.6% died and 8.9% from cardiovascular- and 11.7% from non-cardiovascular causes. Patients treated with CCBs had higher plasma Hcy, fibrinogen levels, and erythrocyte sedimentation rate (all P<0.001). Furthermore, CCB use was positively associated with mortality, also after multivariable adjustments (HRs [95% CIs]: 1.34 [1.15,1.57], 1.35 [1.08,1.70], and 1.33 [1.09,1.64] for total, CVD, and non-CVD death, respectively). Numerically stronger associations were observed among patients not treated with B-vitamins (HR [95% CI]: 1.54 [1.25, 1.88], 1.69 [1.25, 2.30], and 1.41 [1.06, 1.86] for total, CVD deaths, and non-CVD deaths, respectively), whereas no association was seen in patients treated with B-vitamins (HR [95% CI]: 1.15 [0.91, 1.46], 1.09 [0.76, 1.57], and 1.20 [0.88, 1.65]). CONCLUSIONS: In patients with suspected SAP, CCB treatment was associated with increased mortality risk primarily among patients not treated with B-vitamins.
No takes yet. Share an insight, caveat, or question.
Dhar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: